This activity was originally broadcast in conjunction with AMCP 2025.
Program Description
Respiratory syncytial virus (RSV) poses a significant health threat to older adults, contributing to substantial morbidity, hospitalizations, and health care costs annually. Prevention strategies have become a critical focus in clinical practice to reduce morbidity and mortality in older adults. Recently approved vaccines represent new approaches to reduce the burden of RSV-related complications. This program will provide an in-depth look at the pathology, clinical manifestations, and impact on public health of RSV, while highlighting the efficacy, safety, and cost-effectiveness of available vaccines for RSV. Managed care professionals will gain actionable strategies to implement ACIP recommendations, promote equitable access to RSV vaccination, and reduce health care resource utilization.
Target audience: Managed care pharmacists
Type of activity: Application
Release date: April 10, 2025
Expiration date: April 10, 2026
Time to complete activity: 1.5 hours
Learner level: Foundational
Fee: Free
Educational Objectives
At the completion of this activity, participants will be able to:
- Examine the economic and clinical burden of respiratory syncytial virus (RSV) lower respiratory tract disease.
- Analyze the latest clinical data for recently approved and emerging vaccines for RSV.
- Identify managed care initiatives to facilitate the uptake of new RSV immunization strategies to reduce the impact of RSV in adults and on the health care system.
GET STARTED WITH THIS PROGRAM:
Register now to gain access to this program.
Create AccountAlready Registered? Login Here
